Objective: MicroRNAs (miRNAs) have been shown to play an important role in myocardial ischemia/reperfusion (MI/R) injury. This study aimed to determine the role of miR-432 in MI/R injury.

Methods: We established a MI/R injury model by ligation/untying of the left anterior descending coronary artery, and used viral infection to regulate gene expression, such as that of miR-432 and , and used RT-qPCR to detect the expression of the gene at mRNA level. Finally, western blotting and immunochemistry analyses were used to determine the protein level.

Results: The results of this study show that miR-432 is upregulated in the heart following MI/R injury and that miR-432 overexpression showed a significant decrease, while miR-432 knockdown showed a significant increase in the ratio of the infarct area (IA) to the area at risk (AAR) and levels of serum creating phosphokinase (CPK). Moreover, miR-432 augmented the activation of the β-catenin pathway and decreased the rate of apoptosis in the mice heart at 24 hours after MI/R injury by targeting RBM5. At the same time, miR-432 overexpression enhanced HIF-1α activation, while β-catenin deletion attenuated HIF-1α activation induced by miR-432 overexpression. Importantly, β-catenin and HIF-1α knockdown significantly increased the rate of apoptosis and the ratio of IA to AAR and levels of serum CPK induced by miR-432 overexpression at 24 hours after MI/R injury. miR-432 overexpression strongly decreased levels of SOD and GSH-PX activity, and increased levels of MDA activity and the expression of the gp91 protein in the mice hearts at 24 hours after MI/R injury, while miR-432 knockdown exerted an opposite effect. miR-432 was also found to have increased NRF2 protein levels by targeting KEAP1 protein expression. NRF2 knockdown reversed the downregulation of the levels of gp91 protein and MDA, while it also reversed the upregulation of the levels of SOD and GSH-PX induced by miR-432 overexpression in the heart of the mice at 24 hours after MI/R injury.

Conclusion: miR-432 protects against MI/R injury by activating the β-catenin/HIF-1α pathway and augmenting NRF2-mediated anti-oxidative stress.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908467PMC

Publication Analysis

Top Keywords

mi/r injury
28
mir-432 overexpression
24
hours mi/r
16
mir-432
15
injury mir-432
12
induced mir-432
12
mi/r
9
myocardial ischemia/reperfusion
8
injury
8
injury activating
8

Similar Publications

ROS-differentiated release of Apelin-13 from hydrogel comprehensively treats myocardial ischemia-reperfusion injury.

J Control Release

January 2025

Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing 210009, China. Electronic address:

Treatment of myocardial ischemia-reperfusion (MI/R) injury still faces the lack of clinically approved drugs. Apelin-13 is a highly promising drug candidate of MI/R injury, but hampered by its extremely short half-life in plasma. This calls for efficient and smart delivering system for Apelin-13 delivery, but has not been reported.

View Article and Find Full Text PDF

Ropivacaine and celecoxib-loaded injectable composite hydrogel for improved chronic pain-exacerbated myocardial ischemia-reperfusion injury.

J Control Release

January 2025

Department of Joint and Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China. Electronic address:

Chronic pain is a prevalent condition affecting a significant portion of the global population and is known to be associated with an increased risk of cardiovascular diseases. Despite the clinical relevance, the mechanisms underlying the link between chronic pain and myocardial ischemia-reperfusion (MI/R) injury remain poorly understood. This study aimed to investigate the role of the superior cervical ganglion (SCG) in mediating the effects of chronic pain on MI/R injury and to develop a novel therapeutic strategy.

View Article and Find Full Text PDF

Arachidonic acid synergizes with aspirin preventing myocardial ischemia-reperfusion injury and mitigates bleeding risk.

Cardiovasc Res

January 2025

State Key Laboratory of Cardiovascular Disease, Clinical Pharmacology Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.

Aims: The therapeutic efficacy of coronary revascularization is compromised by myocardial ischemia-reperfusion (MI/R) injury. Higher levels of circulating arachidonic acid (AA) are reportedly associated with lower risk of cardiovascular disease. The cyclooxygenase (COX) pathway metabolizes AA into prostaglandins (PGs) and the platelet-activating thromboxane A2 (TXA2), which is inhibited by aspirin.

View Article and Find Full Text PDF

Adipocyte-derived small extracellular vesicles exacerbate diabetic ischemic heart injury by promoting oxidative stress and mitochondrial-mediated cardiomyocyte apoptosis.

Redox Biol

February 2025

Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA; Department of Biomedical Engineering, UAB, Birmingham, AL, USA. Electronic address:

Background: Diabetes increases ischemic heart injury via incompletely understood mechanisms. We recently reported that diabetic adipocytes-derived small extracellular vesicles (sEV) exacerbate myocardial reperfusion (MI/R) injury by promoting cardiomyocyte apoptosis. Combining in vitro mechanistic investigation and in vivo proof-concept demonstration, we determined the underlying molecular mechanism responsible for diabetic sEV-induced cardiomyocyte apoptosis after MI/R.

View Article and Find Full Text PDF

Hypoxia Microenvironment Preconditioning Attenuated Myocardial Ischemia-Reperfusion Injury via Stc1-Mediating Cardiomyocyte Self-Protection and Neutrophil Polarization.

Adv Sci (Weinh)

December 2024

Department of Cardiology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, China.

Ischemic preconditioning (IPC) therapy application to attenuate myocardial ischemia-reperfusion (MI/R) injury in clinical practice remains challenging. The secretome, derived from hypoxia-preconditioned cardiomyocytes (SHPC), potentially mimics the IPC microenvironment and facilitates IPC clinical translation. This study aims to determine whether SHPC can be a feasible alternative to IPC for attenuating MI/R injury, and to identify the functional factor of SHPC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!